We compared the changes in tumor infiltration levels of CD4, CD8, or Foxp3‐positive T cells in tumor tissues before and after EGFR‐TKI treatment, in the patients who developed EGFR‐TKI resistance. This evidence concerns the gene CD8A and neoplasm.